No Prescription

E MYCIN Grans Oral Susp Ery C

No Prescription » Prescription Drugs 6 » E MYCIN Grans Oral Susp Ery C

E-MYCIN 200: Granules for oral suspension. Free flowing pink granules which when mixed with the stated quantity of water provide a cherry flavoured suspension containing erythromycin ethylsuccinate equivalent to 200 mg per 5 mL of erythromycin.IndicationsStreptococcus pyogenes (Group A beta-haemolytic streptococcus): Upper and lower respiratory tract skin and soft tissue infections of mild to moderate severity.When oral medication is preferred for treatment of streptococcal pharyngitis and in long term prophylaxis of rheumatic fever erythromycin is an alternate drug of choice.When oral medication is given the importance of strict adherence by the patient to the prescribed dosage regimen must be stressed. A therapeutic dose should be administered for at least 10 days.Prevention of Initial Attacks of Rheumatic Fever:Penicillin is considered to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Group A beta-haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. The therapeutic dose should be administered for 10 days.Prevention of Recurrent Attacks of Rheumatic Fever:Prevention of Bacterial Endocarditis:Alpha-haemolytic streptococci (viridans group):Staphylococcus aureus: Acute infections of skin and soft tissue of mild to moderate severity. Resistant organisms may emerge during treatment.Streptococcus pneumoniae (Diplococcus pneumoniae): Upper respiratory tract infections (e.g. otitis media pharyngitis) and lower respiratory tract infections (e.g. pneumonia) of mild to moderate degree.Mycoplasma pneumoniae (Eaton agent PPLO):For respiratory infections due to this organism.Haemophilus influenzae: For upper respiratory tract infections of mild to moderate severity. Not all strains of this organism are susceptible to erythromycin at concentrations achieved with usual therapeutic doses; resistant strains may require concomitant therapy with sulphonamides.Ureaplasma urealyticum:For the treatment of urethritis caused by these organisms in adult males.Neisseria gonorrhoeae:ERA-IV (erythromycin lactobionate for injection) in conjunction with erythromycin orally as an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to pencillin. Before treatment of gonorrhoea patients who are suspected of also having syphilis should have a microscopic examination for T. pallidum (by immunofluorescence or darkfield) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter.Chlamydia trachomatis: Erythromycin is indicated for treatment of the following infections caused by Chlamydia trachomatis; conjunctivitis of the newborn pneumonia of infancy and urogenital infections during pregnancy (see Warnings and Precautions). When tetracyclines are contraindicated or not tolerated erythromycin is indicated for the treatment of uncomplicated urethral endocervical or rectal infections in adults due to Chlamydia trachomatis.Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis spinal fluid examinations should be done before treatment and as part of follow-up therapy. Erythromycin should not be used for the treatment of syphilis in pregnancy because it cannot be relied upon to cure an infected foetus.Corynebacterium diphtheriae: As an adjunct to antitoxin to prevent establishment of carriers and to eradicate the organism in carriers.Corynebacterium minutissimum: For the treatment of erythrasma.Entamoeba histolytica: In treatment of intestinal amoebiasis only. Extra-enteric amoebiasis requires treatment with other agents.Listeria monocytogenes: Bordetella pertussis: Legionnaire's Disease: Dosage and AdministrationE-Mycin suspensions and tablets may be administered without regard to meals.Children:Age weight and severity of the infection are important factors in determining the proper dosage. In mild to moderate infections the usual dosage of erythromycin ethylsuccinate for children is 30 to 50 mg/kg/day in equally divided doses every six hours. For more severe infections this dosage may be doubled.If twice-a-day dosage is desired one-half of the total daily dose may be given every 12 hours. Doses may also be given three times daily if desired by administering one-third of the total daily dose every 8 hours.The following dosage schedule is suggested for mild to moderate infectionsBody weight Total daily dose(erythromycin base) <4.5kg 30-50 mg/kg/day 4.5 - 6.8kg 200 mg 6.8 - 11.3kg 400 mg 11.3 - 22.7kg 800 mg 22.7 - 45.4kg 1200 mg Over 45.4kg 1600 mg

Buy E MYCIN Grans Oral Susp Ery C and other Prescription Drugs 6 products online at Medstore.

Buy Online at Medstore - Click Here!

About E MYCIN Grans Oral Susp Ery C:

Product Type: Prescription Drugs 6

E-MYCIN Grans Oral Susp ( Ery C Ery Generic Erythromycin )

E-MYCIN Grans Oral Susp (Ery C Ery Generic Erythromycin)

Ery C Ery Generic Erythromycin

200mg 100mL 200mg 600mL(6 x 100mL) 200mg 300mL(3 x 100mL) 400mg 300mL(3 x 100mL) 400mg 100mL 400mg 600mL(6 x 100mL) Ery C Ery Generic Erythromycin E-MYCIN Grans Oral Susp

View more Prescription Drugs 6

Previous Product  Next Product

No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.